AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37073794 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 0
Study 37073794 — intervention group
Group type: COMPARATOR
Intervention: Control group (discontinued anti-fibrotic therapy > 5 medication half-lives)
Number of subjects: 0
Study 37073797 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary hospitals
Number of subjects: 4978
Study 37073797 — intervention group
Group type: COMPARATOR
Intervention: Tertiary hospitals
Number of subjects: 4978
Study 37073882 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks for up to 96 weeks
Number of subjects: 0
Study 37073926 — intervention group
Group type: EXPERIMENTAL
Intervention: AneuFix elastomer injection into the endoleak cavity and lumbar arteries
Number of subjects: 10
Study 37073926 — intervention group
Group type: COMPARATOR
Intervention: Control group not applicable
Number of subjects: 10
Study 37074202 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1283 vaccine
Number of subjects: 0
Study 37074330 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 0
Study 37074330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37074522 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (MgSO4)
Number of subjects: 60
Study 37074522 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 60
Study 37074571 — intervention group
Group type: EXPERIMENTAL
Intervention: Surufatinib 300 mg QD
Number of subjects: 35
Study 37074571 — intervention group
Group type: EXPERIMENTAL
Intervention: Surufatinib 300 mg QD (pNET cohort)
Number of subjects: 35
Study 37074571 — intervention group
Group type: EXPERIMENTAL
Intervention: Surufatinib 300 mg QD (epNET cohort)
Number of subjects: 35
Study 37074571 — intervention group
Group type: EXPERIMENTAL
Intervention: Surufatinib 300 mg QD (both cohorts)
Number of subjects: 35
Study 37074613 — intervention group
Group type: EXPERIMENTAL
Intervention: Remdesivir (200 mg on day 1 and 100 mg on days 2 and 3)
Number of subjects: 201
Study 37074613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 37074698 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Interpersonal Therapy (IPT)
Number of subjects: 234
Study 37074698 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 234
Study 37074706 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic elective sigmoid resection
Number of subjects: 85
Study 37074706 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 85
Study 37074705 — intervention group
Group type: EXPERIMENTAL
Intervention: Tralokinumab 150 mg
Number of subjects: 301
Study 37074705 — intervention group
Group type: EXPERIMENTAL
Intervention: Tralokinumab 300 mg
Number of subjects: 301
Study 37074705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 37074715 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 135
Study 37074775 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting injectable cabotegravir (CAB-LA) with digital appointment reminders
Number of subjects: 1200
Study 37074775 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting injectable cabotegravir (CAB-LA) with standard of care (SOC) counseling
Number of subjects: 1200
Study 37074775 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention
Number of subjects: 1200
Study 37074775 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital appointment reminders
Number of subjects: 1200
Study 37074775 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) for PrEP choice (oral or CAB-LA)
Number of subjects: 1200
Study 37074948 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive Interviewing
Number of subjects: 151
Study 37074948 — intervention group
Group type: COMPARATOR
Intervention: Control Task
Number of subjects: 151
Study 37074998 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized patient actor (SP) HCW training intervention
Number of subjects: 4595
Study 37074998 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly enrolled YLHIV
Number of subjects: 4595
Study 37074998 — intervention group
Group type: EXPERIMENTAL
Intervention: Wave 3 satisfaction with care scores
Number of subjects: 4595
Study 37075126 — intervention group
Group type: EXPERIMENTAL
Intervention: H1 stem immunogen (H1ssF)
Number of subjects: 0
Study 37075127 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273 COVID-19 vaccine
Number of subjects: 0
Study 37075127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37075129 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 μg of H1ssF once
Number of subjects: 52
Study 37075142 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral oximetry monitoring for the first 72 hours after birth
Number of subjects: 1601
Study 37075142 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1601
Study 37075254 — intervention group
Group type: EXPERIMENTAL
Intervention: 177 Lu-DOTA-EB-TATE without amino acid infusion
Number of subjects: 10
Study 37075254 — intervention group
Group type: COMPARATOR
Intervention: 177 Lu-DOTA-EB-TATE with amino acid infusion
Number of subjects: 10
Study 37075255 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly dose-dense chemotherapy
Number of subjects: 1566
Study 37075255 — intervention group
Group type: COMPARATOR
Intervention: Standard three-weekly carboplatin-paclitaxel regimens
Number of subjects: 1566
Study 37075301 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiprobe PET/MRI in EOAD (n=49)
Number of subjects: 133
Study 37075301 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiprobe PET/MRI in EOAD (n=75)
Number of subjects: 133
Study 37075301 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiprobe PET/MRI in EOAD (n=18)
Number of subjects: 133
Study 37075301 — intervention group
Group type: COMPARATOR
Intervention: Multiprobe PET/MRI in LOAD (n=44)
Number of subjects: 133
Study 37075495 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative frozen section (FS) of sentinel lymph nodes (SLNs)
Number of subjects: 126
Study 37075495 — intervention group
Group type: COMPARATOR
Intervention: Para-aortic lymphadenectomy
Number of subjects: 126
Study 37075617 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobocertinib 160 mg QD
Number of subjects: 164
Study 37075617 — intervention group
Group type: COMPARATOR
Intervention: Real-world treatments (EGFR TKI 20%, immuno-oncology therapy 40%, chemotherapy 40%)
Number of subjects: 164
Study 37075781 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg plus gemcitabine and cisplatin
Number of subjects: 1069
Study 37075781 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus gemcitabine and cisplatin
Number of subjects: 1069
Study 37075847 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal vitamin D supplementation (4400 IU/day)
Number of subjects: 0
Study 37075847 — intervention group
Group type: COMPARATOR
Intervention: Placebo (400 IU/day)
Number of subjects: 0
Study 37075965 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week self-administered dyadic intervention (ReStoreD) consisting of activities completed individually and as a couple.
Number of subjects: 34
Study 37075965 — intervention group
Group type: COMPARATOR
Intervention: Care partner baseline resilience scores
Number of subjects: 34
Study 37076108 — intervention group
Group type: COMPARATOR
Intervention: Endovascular repair (ER)
Number of subjects: 789
Study 37076108 — intervention group
Group type: COMPARATOR
Intervention: Open repair (OR)
Number of subjects: 789
Study 37076132 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-based follow-up strategies for G-(MA)NEC
Number of subjects: 801
Study 37076132 — intervention group
Group type: COMPARATOR
Intervention: Control strategy recommended by the guidelines
Number of subjects: 801
Study 37076142 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative occurrence of nosocomial infections
Number of subjects: 431
Study 37076142 — intervention group
Group type: EXPERIMENTAL
Intervention: Major adverse cardiac events
Number of subjects: 431
Study 37076142 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary complications
Number of subjects: 431
Study 37076142 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute kidney injury
Number of subjects: 431
Study 37076142 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium/acute encephalopathy
Number of subjects: 431
Study 37076142 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality
Number of subjects: 431
Study 37076142 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 431
Study 37076142 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term occurrence of psychopathology
Number of subjects: 431
Study 37076142 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive dysfunction
Number of subjects: 431
Study 37076142 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pain
Number of subjects: 431
Study 37076159 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (TECENTRIQ, F. Hoffmann-La Roche Ltd/Genentech) with local standard-of-care support and Roche DPM Module
Number of subjects: 0
Study 37076159 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible care with subcutaneous atezolizumab (1875 mg; Day 1 of each 21-day cycle) administered in the hospital, followed by 13 cycles at home by a healthcare professional
Number of subjects: 0
Study 37076159 — intervention group
Group type: COMPARATOR
Intervention: Local standard-of-care support without Roche DPM Module
Number of subjects: 0
Study 37076197 — intervention group
Group type: EXPERIMENTAL
Intervention: INFO
Number of subjects: 767
Study 37076197 — intervention group
Group type: EXPERIMENTAL
Intervention: INFO+DELIV
Number of subjects: 767
Study 37076197 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 767
Study 37076252 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine implant (300 mg, three 100 mg implants)
Number of subjects: 365
Study 37076252 — intervention group
Group type: COMPARATOR
Intervention: Placebo (three collagen implants)
Number of subjects: 365
Study 37076424 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-lactam therapeutic drug monitoring (BL TDM)
Number of subjects: 138
Study 37076476 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin plus vitamin D
Number of subjects: 301
Study 37076476 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 301
Study 37076476 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (metformin with or without insulin)
Number of subjects: 301
Study 37076861 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid Doppler peak velocity (CDPV) during end-expiratory occlusion test (EEOt)
Number of subjects: 18
Study 37076861 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrected flow time (cFT) during end-expiratory occlusion test (EEOt)
Number of subjects: 18
Study 37076861 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac index (CI) increase during fluid challenge
Number of subjects: 18
Study 37076884 — intervention group
Group type: EXPERIMENTAL
Intervention: Music Therapy (MT)
Number of subjects: 18
Study 37076884 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 18
Study 37076884 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 18
Study 37076883 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-intubated deep paralysis (NIDP)
Number of subjects: 20
Study 37077305 — intervention group
Group type: EXPERIMENTAL
Intervention: Ophthalmic DMPC-based nanoemulsion (Nanodrop®)
Number of subjects: 0
Study 37077305 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 37077560 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured kangaroo care education program
Number of subjects: 96
Study 37077560 — intervention group
Group type: COMPARATOR
Intervention: Routine care without structured education program
Number of subjects: 96
Study 37077705 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate 6-Month (PP6M)
Number of subjects: 384
Study 37077705 — intervention group
Group type: COMPARATOR
Intervention: Paliperidone Palmitate 3-Month (PP3M)
Number of subjects: 384
Study 37077733 — intervention group
Group type: EXPERIMENTAL
Intervention: Major noncardiac surgery in high-altitude areas
Number of subjects: 196
Study 37077733 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for PCCs
Number of subjects: 196
Study 37077916 — intervention group
Group type: EXPERIMENTAL
Intervention: Golidocitinib (5 - 150 mg single dose; 25 - 100 mg once daily for 14 days)
Number of subjects: 0
Study 37077916 — intervention group
Group type: EXPERIMENTAL
Intervention: Golidocitinib (50 mg) under fed conditions
Number of subjects: 0
Study 37077916 — intervention group
Group type: EXPERIMENTAL
Intervention: Golidocitinib (25 - 150 mg single dose)
Number of subjects: 0
Study 37077916 — intervention group
Group type: EXPERIMENTAL
Intervention: Golidocitinib (50 mg)
Number of subjects: 0
Study 37077916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37077927 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofilm disrupting acne cream 2x
Number of subjects: 0
Study 37077927 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofilm disrupting acne cream 1x
Number of subjects: 0
Study 37077927 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofilm disrupting acne cream without salicylic acid
Number of subjects: 0
Study 37077927 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study 37077927 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% BPO gel
Number of subjects: 0
Study 37078004 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous integrated boost (SIB) with concurrent chemotherapy
Number of subjects: 65
Study 37078188 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBTI)
Number of subjects: 179
Study 37078188 — intervention group
Group type: COMPARATOR
Intervention: Active Control (CTRL) therapy
Number of subjects: 179
Study 37078412 — intervention group
Group type: EXPERIMENTAL
Intervention: Entospletinib 400 mg twice daily with decitabine 20 mg/m²
Number of subjects: 58
Study 37078544 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling with video of endoscopic procedure
Number of subjects: 232
Study 37078544 — intervention group
Group type: COMPARATOR
Intervention: Counselling with no-video
Number of subjects: 232
Study 37078654 — intervention group
Group type: EXPERIMENTAL
Intervention: polydextrose
Number of subjects: 250
Study 37078654 — intervention group
Group type: EXPERIMENTAL
Intervention: psyllium husk
Number of subjects: 250
Study 37078654 — intervention group
Group type: EXPERIMENTAL
Intervention: wheat bran + psyllium husk
Number of subjects: 250
Study 37078654 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 250
Study 37078691 — intervention group
Group type: EXPERIMENTAL
Intervention: Any AF event
Number of subjects: 1002
Study 37078691 — intervention group
Group type: EXPERIMENTAL
Intervention: AF on ECG
Number of subjects: 1002
Study 37078706 — intervention group
Group type: EXPERIMENTAL
Intervention: Orelabrutinib 150 mg once daily
Number of subjects: 106
Study 37078706 — intervention group
Group type: EXPERIMENTAL
Intervention: Orelabrutinib 100 mg twice daily
Number of subjects: 106
Study 37078706 — intervention group
Group type: EXPERIMENTAL
Intervention: Orelabrutinib (both doses)
Number of subjects: 106
Study 37078771 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam (3.375 or 4 g intravenously)
Number of subjects: 778
Study 37078771 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (2 g intravenously; standard care)
Number of subjects: 778
Study 37078953 — intervention group
Group type: EXPERIMENTAL
Intervention: CIK with gemcitabine
Number of subjects: 80
Study 37078953 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study 37078953 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine alone
Number of subjects: 80
Study 37078953 — intervention group
Group type: EXPERIMENTAL
Intervention: CIK alone
Number of subjects: 80
Study 37078969 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-focused Emotion-regulation Therapy (GET)
Number of subjects: 75
Study 37078969 — intervention group
Group type: COMPARATOR
Intervention: Individual Supportive Listening (ISL)
Number of subjects: 75
Study 37079108 — intervention group
Group type: EXPERIMENTAL
Intervention: Queckenstedt's test (QT)
Number of subjects: 14
Study 37079108 — intervention group
Group type: COMPARATOR
Intervention: Resting state
Number of subjects: 14
Study 37079108 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated Queckenstedt's test (QT)
Number of subjects: 14
Study 37079106 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT)
Number of subjects: 572
Study 37079305 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbation-based balance training (PBT) - 4 sessions of 20 minutes each, including 40 slip, trip, or mixed perturbations
Number of subjects: 140
Study 37079305 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory fall rates post-training assessment
Number of subjects: 140
Study 37079305 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory fall rates at 6-month follow-up
Number of subjects: 140
Study 37079305 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory fall rates at 12-month follow-up
Number of subjects: 140
Study 37079305 — intervention group
Group type: COMPARATOR
Intervention: Daily-life fall rates
Number of subjects: 140
Study 37079305 — intervention group
Group type: COMPARATOR
Intervention: Other daily-life fall-related metrics
Number of subjects: 140
Study 37079324 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS) with a single dose of 16 or 18 Gy to involved vertebral levels
Number of subjects: 339
Study 37079324 — intervention group
Group type: COMPARATOR
Intervention: Conventional external beam radiotherapy (cEBRT) with 8 Gy to involved vertebra plus 1 additional vertebra above and below
Number of subjects: 339
Study 37079324 — intervention group
Group type: EXPERIMENTAL
Intervention: SRS
Number of subjects: 339
Study 37079324 — intervention group
Group type: COMPARATOR
Intervention: cEBRT
Number of subjects: 339
Study 37079363 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Acceptance and Commitment Therapy (ACT) intervention
Number of subjects: 30
Study 37079364 — intervention group
Group type: EXPERIMENTAL
Intervention: AOT at the hospital
Number of subjects: 60
Study 37079364 — intervention group
Group type: EXPERIMENTAL
Intervention: AOT at home
Number of subjects: 60
Study 37079364 — intervention group
Group type: COMPARATOR
Intervention: Sham AOT
Number of subjects: 60
Study 37079365 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal provider education intervention
Number of subjects: 20
Study 37079365 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient activation intervention
Number of subjects: 20
Study 37079365 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (provider education and patient activation)
Number of subjects: 20
Study 37079365 — intervention group
Group type: COMPARATOR
Intervention: None of the interventions
Number of subjects: 20
Study 37079367 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time NLP-driven Clinical Decision Support (CDS) tool for opioid misuse screening
Number of subjects: 100
Study 37079367 — intervention group
Group type: EXPERIMENTAL
Intervention: Best Practice Alert (BPA) for screening results with recommendations
Number of subjects: 100
Study 37079367 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation framework with user feedback
Number of subjects: 100
Study 37079385 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 205
Study 37079385 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 205
Study 37079390 — intervention group
Group type: EXPERIMENTAL
Intervention: StableVisc
Number of subjects: 390
Study 37079390 — intervention group
Group type: COMPARATOR
Intervention: ProVisc
Number of subjects: 390
Study 37079393 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-BN-RSV
Number of subjects: 63
Study 37079393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 37079511 — intervention group
Group type: EXPERIMENTAL
Intervention: CardioMEMS PA Sensors
Number of subjects: 101
Study 37079518 — intervention group
Group type: EXPERIMENTAL
Intervention: Rare CIDEC coding variants in patients with small LLD.
Number of subjects: 0
Study 37079518 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with small LLD (indicating better prognosis and better anti-VEGF treatment response).
Number of subjects: 0
Study 37079518 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional analysis of CIDEC alleles in vitro.
Number of subjects: 0
Study 37079569 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies
Number of subjects: 1
Study 37079651 — intervention group
Group type: EXPERIMENTAL
Intervention: UB-612 booster (third dose)
Number of subjects: 1478
Study 37079726 — intervention group
Group type: EXPERIMENTAL
Intervention: UST/MTX (Ustekinumab with Methotrexate), n = 58
Number of subjects: 112
Study 37079726 — intervention group
Group type: COMPARATOR
Intervention: UST/pbo (Ustekinumab with Placebo), n = 54
Number of subjects: 112
Study 37079726 — intervention group
Group type: COMPARATOR
Intervention: UST/pbo
Number of subjects: 112
Study 37079726 — intervention group
Group type: EXPERIMENTAL
Intervention: UST/MTX
Number of subjects: 112
Study 37079726 — intervention group
Group type: EXPERIMENTAL
Intervention: UST/MTX and UST/pbo
Number of subjects: 112
Study 37079726 — intervention group
Group type: EXPERIMENTAL
Intervention: ADA formation
Number of subjects: 112
Study 37079851 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive VR environment (VR Blu)
Number of subjects: 60
Study 37079851 — intervention group
Group type: COMPARATOR
Intervention: Content control with nonimmersive tablet computer (Tablet Blu)
Number of subjects: 60
Study 37079851 — intervention group
Group type: COMPARATOR
Intervention: VR Blank (donning VR headgear without content)
Number of subjects: 60
Study 37079851 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 60
Study 37079894 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin triple therapy (14-day esomeprazole 20 mg, amoxicillin 1.0 g, rifabutin 150 mg twice a day)
Number of subjects: 364